New Paper Published on Modeling and Simulation in Pharmaceuticals

A review article co-authored by Auxilart CEO Junu Kim and Scientific Advisors Yusuke Hayashi, Sara Badr, and Hirokazu Sugiyama was recently published in Current Opinion in Chemical Engineering. The paper explores how modeling and simulation can reduce costs and accelerate pharmaceutical process development across small molecules, biopharmaceuticals, and regenerative medicine, emphasizing the strategic importance of continued investment in these digital technologies.

Read the full article here.

About Auxilart

Auxilart Inc. provides advanced digital simulation solutions based on mechanistic models developed at the University of Tokyo, where the technology has been developed over a decade.

Our Mechanistic model-based simulation technology enables high-precision simulations with minimal data, using only 1% of the data typically required by AI-based methods. By replacing extensive physical experiments with digital simulations, we achieve up to 90% reduction in both cost and time while enhancing productivity.

Founded in 2023, Auxilart has already provided its solutions to Boehringer Ingelheim and major Japanese pharmaceutical companies.

For more information, visit Auxilart's Website.

Media Contact

Auxilart Inc.
Established: July 19, 2023
CEO: Junu Kim
Headquarters: 6F, 1-12-4 Ginza, Chuo-ku, Tokyo, Japan

Contact Person: Kay (Keisuke) Okita
Email: information@auxilart.com